iBio corrects Series G warrant expiration to May 20, 2026; clinical trial for IBIO-600 cleared in Australia

iBio, Inc.

Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).
Outstanding Series G warrants to purchase ~11.07M shares; 36.14M shares of common stock outstanding as of April 17, 2026.
Received CTN acknowledgement from Australia's TGA and ethics approval for Phase 1 trial of IBIO-600; first dosing expected Q2 2026.
Pre-funded warrants for 13.79M shares issued upon exercise of Series G warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.